Our studies suggest that the window of opportunity for effective breast cancer prevention using EGFR inhibitors is a state at which loss of BRCA1 and gain of EGFR have occurred, but the growth factor independence of cancer cells has not yet been established. The gene discussed is EGFR; the disease is breast carcinoma.